- Home
- JNJ
as 11-21-2025 3:36pm EST
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
| Founded: | 1886 | Country: | United States |
| Employees: | N/A | City: | NEW BRUNSWICK |
| Market Cap: | 449.6B | IPO Year: | 1944 |
| Target Price: | $196.60 | AVG Volume (30 days): | 8.9M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 10.35 | EPS Growth: | 71.26 |
| 52 Week Low/High: | $140.68 - $206.94 | Next Earning Date: | 10-14-2025 |
| Revenue: | $92,149,000,000 | Revenue Growth: | 5.08% |
| Revenue Growth (this year): | 6.62% | Revenue Growth (next year): | 5.28% |
Stock Insider Trading Activity of Johnson & Johnson (JNJ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| REED JOHN C | JNJ | EVP, Innovative Medicine, R&D | Oct 17 '25 | Sell | $192.71 | 21,721 | $4,185,793.09 | 10,658 | |
| Taubert Jennifer L | JNJ | EVP, WWC. Innovative Medicine | Sep 4 '25 | Sell | $177.81 | 56,471 | $10,040,882.63 | 178,013.001 |
Latest Johnson & Johnson News
JNJ Breaking Stock News: Dive into JNJ Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Jim Cramer on Kenvue: “I Think It is a Good Situation, Not a Bad One”
Simply Wall St.
2 days ago
How Recent Developments Are Rewriting the Story for Johnson & Johnson
Clinical Trials Arena
2 days ago
Contineum’s MS drug falls short in Phase II trial
Motley Fool
2 days ago
1 Reason Why Shares of Johnson & Johnson Are Surging This Month
The Wall Street Journal
2 days ago
Eli Lilly Reaches $1 Trillion Market Cap on Booming Weight-Loss Drugs
Zacks
2 days ago
Healthcare ETFs to Buy as Big Pharma Rapidly Integrates AI
Investor's Business Daily
3 days ago
This Medical Technology Leader Sees Profit Growth Topping 44%
Zacks
3 days ago
Hologic's GYN Surgical Delivers a Standout Quarter: What's Behind It?
Compare JNJ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JNJ Johnson & Johnson - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.